Affinivax is a clinical stage biotechnology company developing a next generation approach in vaccine technologies to design both preventive and therapeutic vaccines that provide broader protection against infectious and other immune mediated diseases.
Affinivax is advancing a next generation technology platform to enable the development of vaccines and immunotherapies.
Affinivax was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Affinivax is focused on the most challenging bacterial infections, both improving upon existing vaccines and providing vaccines for which there are no prevention strategies available today.
Affinivax's proprietary technology platform, called MAPS, enables the high affinity binding of protective polysaccharides and proteins in a single vaccine or immunotherapy to uniquely induce a broad and protective B and T cell immune response.
Affinivax's lead pneumococcal vaccine, in a partnership with Astellas Pharma, includes 24 pneumococcal serotypes, more than any other vaccine on the market or in clinical testing today. This vaccine has been demonstrated to be safe and highly immunogenic in healthy adults and is currently in Phase 2 clinical trials.
Affinivax is backed by Viking Global Investors, Bill & Melinda Gates Foundation, Bain Capital Life Sciences, Ziff Capital Partners and others. The company raised $120M in a Series B round on Apr 23, 2020. This brings Affinivax's total funding to $122.5M to date.